Department of Planning and Budget
2018 Fiscal Impact Statement

1. **Bill Number:** HB 1177

House of Origin	☐	Introduced	☒	Substitute	☐	Engrossed
Second House	☐	In Committee	☐	Substitute	☐	Enrolled

2. **Patron:** Pillion

3. **Committee:** Commerce and Labor

4. **Title:** Pharmacists and pharmacy practices.

5. **Summary:** Provides that no provider contract between a health carrier or its pharmacy benefits manager and a pharmacy or its contracting agent shall contain a provision (i) authorizing the carrier or its pharmacy benefits manager to charge, (ii) requiring the pharmacy or pharmacist to collect, or (iii) requiring an enrollee to make, a copayment for a covered prescription drug in an amount that exceeds the least of the applicable copayment for the prescription drug that would be payable in the absence of this section; or the cash price the enrollee would pay for the prescription drug if the enrollee purchased the prescription drug without using the enrollee's health plan. Provider contracts between a health carrier or its pharmacy benefits manager and a pharmacy or its contracting agent shall contain specific provisions that allow a pharmacy to disclose to an enrollee information relating to the provisions of this section and the availability of a more affordable therapeutically equivalent prescription drug; sell a more affordable therapeutically equivalent prescription drug to an enrollee if one is available; offer and provide direct and limited delivery services to an enrollee as an ancillary service of the pharmacy. This section shall apply with respect to provider contracts entered into, amended, extended, or renewed on or after January 1, 2019.

6. **Budget Amendment Necessary**: No.

7. **No Fiscal Impact.**

8. **Fiscal Implications:** This bill would not have a fiscal impact on the Commonwealth, the Department of Health Professions, or the Department of Human Resource Management.

9. **Specific Agency or Political Subdivisions Affected:** None.

10. **Technical Amendment Necessary:** No.

11. **Other Comments:** None.